flufenamic acid has been researched along with Alzheimer Disease in 2 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Flufenamic acid and mefenamic acid are efficacious in NLRP3-dependent rodent models of inflammation in air pouch and peritoneum." | 3.83 | Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. ( Allan, SM; Bagnall, J; Baldwin, AG; Booth, SJ; Brough, D; Daniels, MJ; Eder, C; Fasolino, V; Fischer, N; Freeman, S; Galea, J; Harte, MK; Jackson, J; Koziel, V; Latta, C; Lawrence, CB; Paszek, P; Pillot, T; Rivers-Auty, J; Schilling, T; Spencer, NG; Watremez, W; White, CS; Wong, R; Yu, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cotrina, EY | 1 |
| Santos, LM | 1 |
| Rivas, J | 1 |
| Blasi, D | 1 |
| Leite, JP | 1 |
| Liz, MA | 1 |
| Busquets, MA | 1 |
| Planas, A | 1 |
| Prohens, R | 1 |
| Gimeno, A | 1 |
| Jiménez-Barbero, J | 1 |
| Gales, L | 1 |
| Llop, J | 1 |
| Quintana, J | 1 |
| Cardoso, I | 1 |
| Arsequell, G | 1 |
| Daniels, MJ | 1 |
| Rivers-Auty, J | 1 |
| Schilling, T | 1 |
| Spencer, NG | 1 |
| Watremez, W | 1 |
| Fasolino, V | 1 |
| Booth, SJ | 1 |
| White, CS | 1 |
| Baldwin, AG | 1 |
| Freeman, S | 1 |
| Wong, R | 1 |
| Latta, C | 1 |
| Yu, S | 1 |
| Jackson, J | 1 |
| Fischer, N | 1 |
| Koziel, V | 1 |
| Pillot, T | 1 |
| Bagnall, J | 1 |
| Allan, SM | 1 |
| Paszek, P | 1 |
| Galea, J | 1 |
| Harte, MK | 1 |
| Eder, C | 1 |
| Lawrence, CB | 1 |
| Brough, D | 1 |
2 other studies available for flufenamic acid and Alzheimer Disease
| Article | Year |
|---|---|
Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
Topics: Alzheimer Disease; Calorimetry; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Mo | 2021 |
Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Marrow Cells; Cell Death; | 2016 |